Journal Article

DKFZ-2023-01475

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png Fludarabine, cytarabine, and idarubicin with or without venetoclax in patients with relapsed/refractory acute myeloid leukemia.

Shahswar, R. ; Beutel, G. ; Gabdoulline, R. ; Schwarzer, A. ; Kloos, A. ; Koenecke, C. ; Stadler, M. ; Gohring, G. ; Behrens, Y. L. ; Li, Z. ; Dallmann, L.-K. ; Klement, P. ; Albert, C. ; Wichmann, M. ; Alwie, Y. ; Benner, A.DKFZ* ; Saadati, M. ; Ganser, A. ; Thol, F. ; Heuser, M.

2024
Ferrata Storti Foundation Pavia

This record in other databases:  

Please use a persistent id in citations: doi:10.3324/haematol.2023.282912

Abstract: Treatment options for relapsed and refractory acute myeloid leukemia patients (R/R AML) are limited. This retrospective cohort study compares safety and efficacy of fludarabine, cytarabine, and idarubicin (FLA-IDA) with or without venetoclax in patients with R/R AML. Thirty-seven and 81 patients received one course FLA-IDA with or without a 7-day course of venetoclax, respectively. The overall response rate (ORR) was significantly higher in FLAVIDA compared to FLA-IDA treated patients (78% vs. 47%; P=0.001), while MRD was negative at a similar proportion in responding patients (50% vs. 57%), respectively. Eightyone percent and 79% of patients proceeded to allogeneic hematopoietic cell transplantation (alloHCT) or donor lymphocyte infusion (DLI) after FLAVIDA and FLA-IDA, respectively. Event-free and overall survival were similar in FLAVIDA and FLA-IDA treated patients. Refractory patients could be salvaged more successfully after FLA-IDA compared to FLAVIDA pretreatment. Neutrophil and platelet recovery times were similar in the venetoclax and the control group. In conclusion, short-term venetoclax in combination with FLA-IDA represents an effective treatment regimen in R/R AML identifying chemosensitive patients rapidly and inducing MRD negative remission in a high proportion of R/R AML patients.

Note: 2024 Jan 1;109(1):72-83

---

Contributing Institute(s):

1. C060 Biostatistik (C060)

Research Program(s):

1. 313 - Krebsrisikofaktoren und Prävention (POF4-313) (POF4-313)

Appears in the scientific report 2023

---

Database coverage:
; ; Article Processing Charges ; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Clinical Medicine ; Current Contents - Life Sciences ; DOAJ Seal ; Essential Science Indicators ; Fees ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---